Metlinka

Metformin Hydrochloride and Sitagliptin, the active ingredient in Metlinka, is a Biguanide/DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients.

GNH USA supplies Metlinka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metlinka is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by elevated blood glucose.

Type 2 diabetes mellitus: improves glycaemic control when used with diet and exercise, reducing fasting plasma glucose and HbA1c levels.

Metlinka may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea - Diarrhoea - Abdominal discomfort - Headache - Mild hypoglycaemia (especially when combined with other antidiabetics) - Upper respiratory tract infection

Serious or Rare Side Effects: - Lactic acidosis - Severe hypoglycaemia - Pancreatitis - Acute renal failure - Hepatic dysfunction - Anaphylactic reactions

Before prescribing Metlinka, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Renal impairment: assess kidney function and adjust dose or avoid if eGFR <30 mL/min/1.73 m². - Hepatic disease: use with caution due to increased risk of lactic acidosis. - Heart failure: monitor for signs of fluid overload and metabolic acidosis. - Concomitant contrast media: discontinue metformin before and after iodinated contrast procedures. - Store at ambient temperature (below 25°C): keep in the original container, protect from moisture and light.

Metlinka can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of metformin‑associated lactic acidosis; discontinue metformin before and after use. - Insulin or sulfonylureas: may cause severe hypoglycaemia; dose adjustments required.

Moderate Interactions (Monitor Closely): - Cimetidine: can raise sitagliptin plasma concentrations. - Rifampicin: may reduce sitagliptin exposure. - Diuretics: may affect renal clearance of metformin, necessitating monitoring of renal function.